Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLRX Salarius Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: SLRX
Price (delayed)
$0.8305
Market cap
$1.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.82
Enterprise value
$80,561
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius' lead candidate, seclidemstat, is being studied as a potential treatment
Highlights
The EPS has soared by 76% YoY and by 17% from the previous quarter
The debt has contracted by 49% from the previous quarter and by 4% YoY
SLRX's equity has shrunk by 98% YoY and by 96% QoQ
The quick ratio has dropped by 78% year-on-year and by 51% since the previous quarter
Key stats
What are the main financial stats of SLRX
Market
Valuations
Earnings
Shares outstanding
2.13M
Market cap
$1.77M
Enterprise value
$80,561
Price to earnings (P/E)
N/A
Price to book (P/B)
23.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$5.68M
Net income
-$5.57M
EBIT
-$5.57M
EBITDA
-$5.57M
Free cash flow
-$4.35M
Per share
Balance sheet
Liquidity
EPS
-$4.82
EPS diluted
-$4.82
Free cash flow per share
-$2.62
Book value per share
$0.04
Revenue per share
$0
TBVPS
$1.41
Total assets
$2.34M
Total liabilities
$2.28M
Debt
$112,230
Equity
$61,866
Working capital
$27,560
Debt to equity
1.81
Current ratio
1.01
Quick ratio
0.79
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-174.4%
Return on equity
-324.1%
Return on invested capital
N/A
Return on capital employed
-9,003.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLRX stock price
How has the Salarius Pharmaceuticals stock price performed over time
Intraday
-2.27%
1 week
7.72%
1 month
23.64%
1 year
-78.81%
YTD
-54.86%
QTD
10.15%
Financial performance
How have Salarius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$5.68M
Net income
-$5.57M
Gross margin
N/A
Net margin
N/A
The operating income rose by 39% YoY
SLRX's net income is up by 38% year-on-year
Price vs fundamentals
How does SLRX's price correlate with its fundamentals
Growth
What is Salarius Pharmaceuticals's growth rate over time
Valuation
What is Salarius Pharmaceuticals stock price valuation
P/E
N/A
P/B
23.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 76% YoY and by 17% from the previous quarter
SLRX's equity has shrunk by 98% YoY and by 96% QoQ
Efficiency
How efficient is Salarius Pharmaceuticals business performance
SLRX's ROE has plunged by 113% YoY and by 52% from the previous quarter
The ROA has shrunk by 56% YoY and by 20% QoQ
Dividends
What is SLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLRX.
Financial health
How did Salarius Pharmaceuticals financials performed over time
Salarius Pharmaceuticals's total assets is 2.7% higher than its total liabilities
The company's total liabilities has surged by 85% YoY and by 51% QoQ
The quick ratio has dropped by 78% year-on-year and by 51% since the previous quarter
The debt is 81% more than the equity
SLRX's equity has shrunk by 98% YoY and by 96% QoQ
The debt has contracted by 49% from the previous quarter and by 4% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.